Key Highlights
- VKTX shares climbed more than 39% during pre-market hours following the announcement of VK2735 maintenance phase trial outcomes
- The 17.5mg weekly dose of VK2735 delivered 22% weight reduction versus placebo over a 33-week period
- During the maintenance segment, bi-weekly administration maintained up to 97% of achieved weight loss, while monthly dosing preserved up to 90%, compared to just 61% retention with placebo
- VK2735 demonstrated strong tolerability with gastrointestinal side effects matching placebo levels
- The company reported $502 million in cash reserves as of Q2 end, while Oppenheimer sustained its $100 target price prior to data disclosure
Shares of Viking Therapeutics surged more than 39% in early Tuesday trading, pushing the stock to $42 and nearing its 52-week peak of $43.15. The dramatic rally followed the biotechnology company’s disclosure of positive top-line data from the maintenance portion of its VK2735 clinical trial, evaluating the injectable dual GLP-1/GIP receptor agonist.
Viking Therapeutics, Inc., VKTX
The data emerged from the VK2735-102 clinical trial, structured as a two-phase investigation. During the initial 21-week induction phase, participants administered once-weekly VK2735 achieved weight reductions ranging from approximately 16% to 19%, while the placebo cohort experienced essentially no weight change.
The maintenance phase data provided the catalyst for Tuesday’s dramatic price movement. Over a 12-week maintenance period, subjects transitioning to bi-weekly dosing maintained as much as 97% of their previously achieved weight loss. Participants shifting to monthly administration preserved up to 90% of their weight reduction. Meanwhile, the placebo group retained merely 61% of initial weight loss.
Across the complete 33-week duration of both study phases, participants on the 17.5mg weekly regimen experienced 22% weight loss when adjusted for placebo.
Favorable Safety Data Impresses Market
The drug’s tolerability profile emerged as another significant positive element. Gastrointestinal adverse events recorded during the maintenance period were statistically similar to those observed in the placebo arm.
Discontinuation rates remained minimal throughout the trial. A single participant withdrew during the induction phase due to an adverse event. During the maintenance phase, one subject in the bi-weekly cohort and one in the monthly dosing group discontinued participation.
These tolerability metrics carry substantial weight in a therapeutic category where gastrointestinal complications have posed ongoing challenges with rival medications.
Prior to the data announcement, Oppenheimer had retained an Outperform rating alongside a $100 price target. The investment firm had indicated that many market participants presumed Eli Lilly’s tirzepatide would control the GLP-1/GIP market segment, suggesting VK2735 maintenance results could reframe competitive discussions around dosing schedules and patient compliance.
Future Development Path
Viking announced intentions to investigate oral maintenance dosing protocols for VK2735 through Part 2 of the ongoing trial, expanding beyond the subcutaneous delivery method evaluated in current results.
The biotechnology firm had previously communicated to investors that maintenance phase data would arrive during the third quarter of 2026. That timeline remained unchanged.
As of the second quarter 2026 conclusion, Viking maintained $502 million in cash reserves, providing sufficient financial resources to advance its development pipeline through subsequent clinical stages.
Tuesday’s stock movement occurred independently of broader market trends. The S&P 500 advanced a modest 0.1%, the Nasdaq registered negligible gains at +0.05%, and the Dow Jones increased 0.3%. The VKTX rally was purely driven by company-specific catalysts.
Having previously reached a 52-week high of $43.15, the pre-market trading price of $42 positions the stock within striking distance of that benchmark once again.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
